Hedy Kindler to Risk Factors
This is a "connection" page, showing publications Hedy Kindler has written about Risk Factors.
Connection Strength
0.240
-
[Screening for risk of child abuse and neglect. A practicable method?]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010 Oct; 53(10):1073-9.
Score: 0.045
-
Venous Thromboembolism in Peritoneal Mesothelioma: Uncovering the Hidden Risk. Ann Surg Oncol. 2024 May; 31(5):3339-3349.
Score: 0.029
-
Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). J Clin Oncol. 2022 03 01; 40(7):740-751.
Score: 0.025
-
The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance). Cancer Epidemiol Biomarkers Prev. 2020 08; 29(8):1692-1695.
Score: 0.022
-
Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). J Natl Cancer Inst. 2019 02 01; 111(2):170-179.
Score: 0.020
-
Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS One. 2018; 13(7):e0199244.
Score: 0.019
-
Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol. 2018 04 10; 36(11):1112-1120.
Score: 0.019
-
Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev. 2018 04; 27(4):438-445.
Score: 0.019
-
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 01; 20(23):5927-36.
Score: 0.015
-
Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance). PLoS One. 2014; 9(6):e99816.
Score: 0.015
-
Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage. 2012 Feb; 43(2):205-17.
Score: 0.012